Navigation Links
OHSU Cancer Institute researchers find connection between protein, prognosis in breast cancer
Date:4/13/2008

PORTLAND, Ore. Oregon Health & Science University Cancer Institute researchers have found that a tumor protein present in an aggressive form of breast cancer is related to a poor prognosis.

The presence of the protein, called growth factor receptor-bound protein-7, often referred to as GRB-7, in breast cancer tumors, is strongly related to the growth and spread of the cancer, according to principal investigator Shiuh-Wen Luoh, M.D., Ph.D., assistant professor of medicine (hematology/medical oncology) in the OHSU School of Medicine.

The research will be presented Sunday, April 13, at 1 p.m. at the annual American Association for Cancer Research meeting in San Diego.

The GRB-7 protein previously has been shown to be important to cell communication in the spread of cancer. The GRB-7 gene is located close to the HER-2/Neu gene that regulates breast cancer growth. The OHSU Cancer Institute researchers discovered that the levels of GRB-7 protein are often heightened at the same time that HER-2/Neu levels are high. Also, not infrequently, they found breast tumors that overexpressed one but not the other protein. Overexpression means that there is an abundant presence of the protein.

It is surprising that we found discordance in the overexpression of these genes because they are so close together, Luoh said.

Researchers analyzed 563 primary breast cancer specimens. The samples were collected during a 20 year period for the OHSU Cancer Institute Breast Tumor and Clinical Data Repository.

The OHSU study shows that one in six breast tumors have high GRB-7 protein. These tumors have more aggressive, fast-growing and fast-spreading characteristics. HER-2/Neu positive tumors do not show these same features.

We think that identifying the individual contribution of the GRB-7 and its interaction with HER-2/ Neu gene may eventually help physicians better predict the clinical course of breast cancer in their patients. Also, new treatments might be designed to interfere with the actions of GRB-7 that can stop the growth and spread of a portion of breast cancer tumors, Luoh said.

Researchers have known that not all HER-2/Neu positive breast cancers shrink or slow their growth when treated with Trastuzumab or Lapatinib, targeted therapies against HER-2/Neu. The researchers speculate that GRB-7 might influence a tumors response to treatment. These findings are preliminary but could eventually lead to a clinical test for GRB-7 and better treatment for patients with GRB-7 positive breast tumors, Luoh explained.


'/>"/>

Contact: Christine Decker
503-494-8231
Oregon Health & Science University
Source:Eurekalert

Related medicine news :

1. Drinking May Raise Breast Cancer Risk
2. Biomarker May Predict Response to Cancer Therapy
3. Breast Cancer Vaccine Works Against Deadlier Form of Disease
4. Karmanos Researchers Report Enhanced Chemosensitivity of Pancreatic Cancer Cells by Black Seed Component
5. Penn researchers find targeted therapy combination overcomes treatment resistance in liver cancer
6. Susan G. Komen for the Cure(R) Calls on Policymakers to Address Unfairness in Breast Cancer Incidence and Mortality
7. Radiation beneficial for older breast cancer patients
8. Cancer Drug Trials Often Halted Early
9. Mammography plus sonography can help rule out breast cancer in patients with palpable lesions
10. Newly diagnosed breast cancer patients benefit from use of USFNA of lymph nodes
11. New technique in treating patients with liver cancer proves effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Rey, CA (PRWEB) , ... March 23, 2017 ... ... its customizable coding audit software solution, iCode Assurance, at HCCA’s 21st annual Compliance ... optimizes and accelerates the coding audit process for all medical chart types with ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... “Wounded Woman ... “Wounded Woman Be Ye Healed-Passing On A Legacy” is the creation of published author, ... founder of Comfortbearers grief ministry. She has been happily married to her husband, ...
(Date:3/23/2017)... ... 2017 , ... “A Respectful Response To Atheist Manifesto”: theological ... Manifesto” is the creation of published author Richard Hostetter, a former missionary in ... holds graduate degrees from Kent State University and the University of Ghana. , ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... the publication of “Profiling protein expression in circulating tumor cells using microfluidic western ... the use of the Vortex technology to capture CTCs and a ...
(Date:3/22/2017)... (PRWEB) , ... March 23, 2017 , ... ... technologies and development solutions for drugs, biologics and consumer health products, today announced ... BioPharma Asia Convention, currently taking place at the Suntec Singapore International Exhibition & ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... Mass. , March 23, 2017 Merrimack ... enrollment of its first patient in a Phase 1 ... antibody-directed nanotherapeutic (ADN) that encapsulates a novel taxane and ... is overexpressed in 50-100% of many major tumor types, ... "The initiation of this study is an ...
(Date:3/23/2017)... , March 23, 2017 Global Colposcope Market ... on the Colposcope in Global market, especially in North ... Asia-Pacific , South America , ... report categorizes the market based on manufacturers, regions, type and application. ... Browse 190 Tables ...
(Date:3/23/2017)... 23, 2017 NeuroVive Pharmaceutical AB (Nasdaq ... that the English version of the Annual report for 2016 ... ... NeuroVive NeuroVive Pharmaceutical AB is a leader in ... development of medicines that preserve mitochondrial integrity and function in ...
Breaking Medicine Technology: